Carteolol/latanoprost - Otsuka Pharmaceutical
Alternative Names: Carteolol hydrochloride/latanoprost; Mikeluna; OPC-1085ELLatest Information Update: 17 May 2023
At a glance
- Originator Otsuka Pharmaceutical
- Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Small molecules
- Mechanism of Action Beta adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
Most Recent Events
- 01 Jul 2019 Chemical structure information added
- 30 Mar 2018 Otsuka Pharmaceutical suspends a clinical trial for Glaucoma in Japan (UMIN000030288)
- 22 Nov 2017 Otsuka Pharmaceutical initiates enrolment in a trial for Glaucoma in Japan (UMIN000030288)